Modulated electro-hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial

Kidong Kim, Jae-Hoon Kim, Seung Cheol Kim, Yong Beom Kim, Byung-Ho Nam, Jae Hong No, Hanbyoul Cho, Woong Ju, Dong Hoon Suh, Yun Hwan Kim, Kidong Kim, Jae-Hoon Kim, Seung Cheol Kim, Yong Beom Kim, Byung-Ho Nam, Jae Hong No, Hanbyoul Cho, Woong Ju, Dong Hoon Suh, Yun Hwan Kim

Abstract

The present study (KGOG 3030) aimed to evaluate the safety of modulated electro-hyperthermia (mEHT) therapy with weekly administration of paclitaxel or cisplatin in female patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. A total of 12 patients were randomized into the paclitaxel or cisplatin arm at a 1:1 ratio. Patients received weekly administration of paclitaxel (70 mg/m2) or cisplatin (40 mg/m2) intravenously on days 1, 8 and 15, and underwent mEHT therapy for 1 h on days 1, 4, 8, 11, 15, 18, 21 and 24 for each 4-week cycle. The primary endpoint was the occurrence of dose-limiting toxicity (DLT). The secondary endpoints were treatment-emergent adverse events (TEAEs), objective response rate, carbohydrate antigen 125 (CA125) response rate, progression-free survival (PFS) and overall survival (OS). In total, 16 patients were recruited, but four patients dropped out. None of the 12 remaining patients (6 each in the two arms) experienced DLT. Overall, 0 and 4 grade 3 TEAEs (anemia, nausea, neutrophil count decreased and platelet count decreased) occurred in the paclitaxel and cisplatin arm, respectively. Furthermore, one confirmed partial response and two CA125 responses were observed in the cisplatin arm. The median PFS time in the paclitaxel and cisplatin arms was 3.0 months (range, 1.7-4.6 months) and 6.8 months (range, 3.9-11.8 months), respectively, while the median OS time was 11.5 months (range, 8.4-28.8+ months) and not reached (range, 3.9-38.5+ months), respectively. In conclusion, mEHT therapy with weekly paclitaxel or cisplatin appeared safe and warrants further investigation. The present trial was registered with www.clinicaltrials.gov on January 22, 2015 (trial registration no. NCT02344095).

Keywords: cisplatin; induced hyperthermia; ovarian epithelial carcinoma; paclitaxel; toxicity.

Conflict of interest statement

The authors declare that they have no competing interests.

Copyright: © Kim et al.

Figures

Figure 1
Figure 1
Flowchart depicting the movement of patients throughout the present trial.

References

    1. Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, Ray-Coquard I, Sehouli J, Harter P, du Bois A. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23:2605–2612. doi: 10.1093/annonc/mds203. AGO and GINECO study group.
    1. Li Z, Sun Q, Huang X, Zhang J, Hao J, Li Y, Zhang S. The efficacy of radiofrequency hyperthermia combined with chemotherapy in the treatment of advanced ovarian cancer. Open Med (Wars) 2018;13:83–89. doi: 10.1515/med-2018-0013.
    1. Vasanthan A, Mitsumori M, Park JH, Zhi-Fan Z, Yu-Bin Z, Oliynychenko P, Tatsuzaki H, Tanaka Y, Hiraoka M. Regional hyperthermia combined with radiotherapy for uterine cervical cancers: A multi-institutional prospective randomized trial of the international atomic energy agency. Int J Radiat Oncol Biol Phys. 2005;61:145–153. doi: 10.1016/j.ijrobp.2004.04.057.
    1. Yang W, Han GH, Shin HY, Lee EJ, Cho H, Chay DB, Kim JH. Combined treatment with modulated electro-hyperthermia and an autophagy inhibitor effectively inhibit ovarian and cervical cancer growth. Int J Hyperthermia. 2019;36:9–20. doi: 10.1080/02656736.2018.1528390.
    1. Lee SY, Lee NR, Cho DH, Kim JS. Treatment outcome analysis of chemotherapy combined with modulated electro-hyperthermia compared with chemotherapy alone for recurrent cervical cancer, following irradiation. Oncol Lett. 2017;14:73–78. doi: 10.3892/ol.2017.6117.
    1. Minnaar CA, Kotzen JA, Ayeni OA, Naidoo T, Tunmer M, Sharma V, Vangu MDT, Baeyens A. The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial. PLoS One. 2019;14(e0217894) doi: 10.1371/journal.pone.0217894.
    1. Yoo HJ, Lim MC, Seo SS, Kang S, Joo J, Park SY. Phase I/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer. Jpn J Clin Oncol. 2019;49:832–838. doi: 10.1093/jjco/hyz071.
    1. Hegyi G, Szigeti GP, Szász A. Hyperthermia versus oncothermia: Cellular effects in complementary cancer therapy. Evid Based Complement Alternat Med. 2013;2013(672873) doi: 10.1155/2013/672873.
    1. Yang KL, Huang CC, Chi MS, Chiang HC, Wang YS, Hsia CC, Andocs G, Wang HE, Chi KH. In vitro comparison of conventional hyperthermia and modulated electro-hyperthermia. Oncotarget. 2016;7:84082–84092. doi: 10.18632/oncotarget.11444.
    1. Szasz AM, Minnaar CA, Szentmártoni G, Szigeti GP, Dank M. Review of the clinical evidences of modulated electro-hyperthermia (mEHT) method: An update for the practicing oncologist. Front Oncol. 2019;9(1012) doi: 10.3389/fonc.2019.01012.
    1. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152:726–732. doi: 10.1136/bmj.c332. CONSORT Group.
    1. Haveman J, Bergs JWJ, Franken NAP, van Bree C, Stalpers LJA. Effect of hyperthermia on uptake and cytotoxicity of cisplatin in cultured murine mammary carcinoma cells. Oncol Rep. 2005;14:561–567. doi: 10.3892/or.14.2.561.
    1. Raaphorst GP, Yang DP. The evaluation of thermal cisplatin sensitization in normal and XP human cells using mild hyperthermia at 40 and 41 degrees C. Anticancer Res. 2005;25:2649–2653.
    1. Markman M, Blessing J, Rubin SC, Connor J, Hanjani P, Waggoner S. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A gynecologic oncology group study. Gynecol Oncol. 2006;101:436–440. doi: 10.1016/j.ygyno.2005.10.036. Gynecologic Oncology Group.
    1. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649–655.
    1. U.S.Department of Health and Human Services: Common Terminology Criteriafor Adverse Events (CTCAE). Version 4.0. . Accessed June 14, 2010.
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–247. doi: 10.1016/j.ejca.2008.10.026.
    1. Jiang Z, Yan W, Ming J and Y. Docetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer. A preliminary study. 2007;7(189) doi: 10.1186/1471-2407-7-189.
    1. Leal BZ, Meltz ML, Mohan N, Kuhn J, Prihoda TJ, Herman TS. Interaction of hyperthermia with taxol in human MCF-7 breast adenocarcinoma cells. Int J Hyperthermia. 1999;15:225–236. doi: 10.1080/026567399285747.
    1. Rietbroek RC, Katschinski DM, Reijers MH, Robins HI, Geerdink A, Tutsch K, d'Oleire F, Haveman J. Lack of thermal enhancement for taxanes in vitro. Int J Hyperthermia. 1997;13:525–533. doi: 10.3109/02656739709023551.
    1. van der Burg MEL, de Wit R, Van Putten WL, Logmans A, Kruit WH, Stoter G, Verweij J. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer. 2002;86:19–25. doi: 10.1038/sj.bjc.6600002.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit